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Abstract
The development of an effective malaria vaccine has taken many decades, but there is now a good chance that the ﬁrst malaria vaccine
will be licensed within the next few years. However, this vaccine (RTS,S) will not be fully effective, and more efﬁcacious, second-genera-
tion vaccines will be needed. Good progress is being made in the development of potential vaccines directed at each of the three main
stages of the parasite’s life cycle, with a variety of different approaches, but many challenges remain, e.g. overcoming the problem of
polymorphism in many key parasite antigens. It is likely vaccines that are effective enough to block transmission, and thus contribute to
increasing drives towards malaria elimination, will need to contain antigens from different stages of the parasite’s life cycle.
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Introduction
There has been considerable progress in the control of
malaria in recent years, as a result of increased investment,
now about $2 billion a year, by organizations such as the
Global Fund, the President’s Malaria Initiative, the World
Bank and bilateral donors. This investment has allowed scal-
ing up of the few effective malaria control tools that are
currently available: effective treatment with artemisinin com-
bination therapy, long-lasting insecticide-treated bednets, and
indoor residual spraying. When these interventions have
been deployed widely, a marked reduction in the incidence
of malaria has been reported from a number of countries in
Asia and sub-Saharan Africa, where malaria transmission has
traditionally been low or moderate [1]. These successes have
led to an increased interest in the possibility of malaria elimi-
nation (Table 1) as a feasible medium-term goal in some
countries. Malaria eradication, a taboo topic in the malaria
community for over three decades following the failure of
the ﬁrst global effort to achieve this goal, is a more distant
prospect.
However, despite these recent successes, malaria remains
largely uncontrolled in many parts of sub-Saharan Africa and
in a few countries in Asia, such as Myanmar, and still causes
nearly 800 000 deaths each year, mainly in children in sub-
Saharan Africa [2–4]. This large number of deaths could be
reduced further by increasing coverage with existing control
tools, but it is generally recognized that this would not be
sufﬁcient to achieve the high level of control that would be
needed to make elimination a credible objective. Further-
more, the limited successes that have been achieved in high-
transmission areas in sub-Saharan Africa are threatened by
the potential spread of artemisinin-resistant strains of Plasmo-
dium falciparum from Southeast Asia [5] and by the spread of
strains of Anopheles gambiae that are highly resistant to pyre-
throid insecticides [6]. Additional tools will be required to
achieve effective malaria control in these high-transmission
areas.
The malaria-endemic world can now be divided into two
areas: those where effective malaria control has been
achieved and where malaria elimination is a feasible short-
term to medium-term goal; and those where malaria has yet
to be brought under effective control and where elimination
is a distant prospect [4,7]. Malaria vaccines have an impor-
tant role to play in each of these situations, but different
types of vaccine will be needed for each. In this article, we
review the progress that is being made in the development
of vaccines that ﬁt these target product proﬁles, and discuss
how they might be deployed.
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Development of Malaria Vaccines
Malaria parasites and their life cycles
Humans may be infected by ﬁve species of Plasmodium
(Fig. 1). Both P. falciparum and Plasmodium vivax can cause
severe disease, but P. falciparum has been the focus of most
vaccine-related research. Plasmodium ovale and Plasmodium
malariae are rarely considered as vaccine targets, and Plasmo-
dium knowlesi, a primate malarial parasite that was used in
early blood-stage vaccine studies [8,9], has only recently
emerged as the cause of a naturally acquired infection in
humans [10].
The life cycle of human malaria parasites is complex. The
infection commences with the inoculation of a small number
of sporozoites (usually <100) through the bite of an infected
mosquito. Some sporozoites are retained in the tissues
around the bite, but others pass through the circulation to
the liver, where they develop into schizonts. Development in
the liver involves a 10 000-fold or more increase in parasite
numbers. Following an incubation period of about 10 days,
schizonts rupture, leading to invasion of erythrocytes by
merozoites. Progressive cycles of multiplication within ery-
throcytes every 48 or 72 h, according to the species, results
in the clinical features of the disease. A few P. vivax (and
P. ovale) sporozoites become non-dividing hypnozoites that
remain dormant in liver cells for weeks, months or years
before reactivating. Finally, unknown factors [11] lead to the
conversion of a small number of asexual forms into the male
and female gametocytes that are required to initiate develop-
ment in the vector mosquito when she takes a blood meal.
Attempts are being made to develop vaccines that target
each stage of the life cycle [12] (Table 2).
Pre-erythrocytic vaccines
There is a clear logic to vaccination directed at the sporozo-
ite stage of the parasite, as the number of parasites inocu-
lated by a mosquito is relatively small [13], creating a
bottleneck in the parasite’s life cycle (Table 3).
The earliest successful attempts at developing a pre-eryth-
rocytic vaccine were made in chickens injected with large
numbers of sporozoites of Plasmodium gallinaceum inactivated
by UV irradiation [14]. Subsequently, Nussenzweig et al. [15]
showed that vaccination with X-irradiated Plasmodium berghei
sporozoites fully protected mice against sporozoite challenge.
Similar high levels of protection were obtained in humans,
using multiple bites by irradiated mosquitoes infected with
P. falciparum [16].
Immunization with the dominant sporozoite surface pro-
tein molecule, circumsporozoite protein (CSP), gave protec-
tion in rodents and, following the cloning of CSP of
FIG. 1. Malaria life cycle showing (1) pre-
erythrocytic sporozoite inoculation and inva-
sion of the liver, (2) asexual blood stages, and
(3) the sexual cycle and sporogony in the
mosquito. Vaccines are being developed
against each of these phases of the life cycle.
Adapted from Ref. [55] and reprinted with
permission.
TABLE 1. Deﬁnitions
Controlled low-endemicity malaria
Endemic malaria transmission has been reduced to a very low level.
Transmission still occurs but does not constitute a major public health burden
Controlled non-endemic malaria
Endemic transmission has been interrupted but malaria resulting from
onward transmission from imported infections continues at a level that
prevents elimination
Elimination
Interventions have interrupted endemic transmission and limited onward
transmission from imported infections below a threshold at which the risk
of re-establishment is minimal
Eradication
Cessation of all naturally occurring transmission of one or more species of
human malaria parasites
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P. falciparum, a series of recombinant and synthetic candidate
vaccines based on parts of CSP were tested in small-scale
human trials. Most gave little or no protection, with the
notable exception of one called RTS,S, a construct of CSP
with the hepatitis B virus surface antigen [17]. A series of tri-
als with this construct, given with a powerful adjuvant over a
period of 15 years, showed 30–50% protection against clini-
cal episodes of malaria (Fig. 2) [18] and, in infants, there was
a strong correlation between anti-CSP antibodies and the
risk of clinical malaria. This vaccine is now undergoing a
phase 3 trial at 11 sites in seven countries in Africa, involving
over 15 000 children, and is likely to be the ﬁrst malaria vac-
cine to be licensed. A key to the success of RTS,S has been
its use with the powerful adjuvant AS02, an oil in water
emulsion containing monophosphoryl lipid A and Quil A
saponin, or with AS01, which consists of monophosphoryl
lipid A, Quil A saponin and liposomes.
As illustrated by RTS,S, it has proved difﬁcult to induce
high enough immune responses to several malaria antigens
to provide protection, and the lack of availability of powerful
adjuvants that can be used safely in humans and that are not
protected by company patents has hindered malaria vaccine
development by academic groups. However, steps are being
taken to overcome this by making new adjuvants more
widely available through non-proﬁt organizations, such as the
Infectious Disease Research Institute in the USA and
TRANSVAC in Europe.
Despite its early success, utilization of whole sporozoites
as a vaccine was initially considered to be an impracticable
approach, because of the problems of obtaining a sufﬁcient
number of sporozoites free enough of contaminants to be
used as a vaccine. However, outstanding progress has been
made recently in producing an irradiation-attenuated sporo-
zoite vaccine that is compliant with regulatory requirements
for clinical use [19]. The initial clinical trial using sporozoites
given intradermally or subcutaneously showed limited pro-
tection, but intravenous inculation may be more successful.
An alternative approach is to produce genetically attenuated
parasites. One or two genes are deleted, making the parasite
capable of only limited development in the liver. Experimen-
tally, double knockouts have proved to be highly effective
vaccines, and P. falciparum genetically attenuated parasites
gave good protection in a humanized mouse model [20,21].
Recently, another way of inducing protective immunity in
humans with sporozoites has been reported. A high level of
protection was achieved when volunteers were exposed to
bites of P. falciparum-infected mosquitoes and given chloro-
quine at the same time; immunity persisted for more than
2 years in four of six volunteers [22]. Further investigations
need to address issues of strain speciﬁcity, efﬁcacy in ende-
mic populations, and whether the immunosuppressive effects
of blood-stage infections underlie the reason why this level
of protection is not achieved during natural infection [23].
Elucidating the mechanisms of immunity induced in this
experiment may provide important information to guide
future vaccine development.
Blood-stage vaccines
The fact that it is possible to develop some degree of pro-
tective immunity to the blood stages of P. falciparum was
established many years ago, when it was shown that immuno-
TABLE 2. Malaria vaccine targets
Pre-erythrocytic stages
These vaccines are directed against either the invasive sporozoite or the
early stage of development in the liver
Asexual blood cycle
These vaccines are designed to stop invasion of erythrocytes or to kill
intra-erythrocytic parasites
Sexual cycle
These vaccines aim to stop mosquitoes becoming infected by preventing
parasite fertilization and/or by inhibiting early development in the insect vector
FIG. 2. Kaplan–Meier curves showing the cumulative proportion of
clinical Plasmodium falciparum cases after vaccination of children with
RTS,S/ASOIE as compared with controls given rabies vaccine in (a)
Korogwe, Tanzania and (b) Kiliﬁ, Kenya [18].
TABLE 3. Pre-erythrocytic-stage vaccine strategies
Subunit vaccines based on the sporozoite surface proteins circumsporozoite
surface protein (CSP) and thrombospondin-related adhesion protein (TRAP)
Viral particle coexpression of CSP, e.g. RTS,S
Viral vector, e.g. adenovirus, expression forms of CSP and TRAP
Recombinant liver-stage antigens LSAI and LSA3
Sporozoites attenuated by irradiation or genetically
Sporozoite infections controlled by chemotherapy
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globulin obtained from adults who were semi-immune to
P. falciparum cleared parasites when given to infected chil-
dren [24]. Building on this ﬁnding, attempts have been made
to develop vaccines against the asexual blood-stage parasites
by inducing an immune response that either blocks invasion
of erythrocytes or inhibits their subsequent multiplication.
Although a large number of blood-stage vaccines have been
developed and tested in preclinical and clinical trials [25,26]
(Table 4), almost all have been based on a small number of
antigens expressed on merozoites [3,27]. Although protec-
tion has been achieved in experimental animals, little clinical
success has so far been achieved in humans with blood-stage
vaccines.
The challenges in the development of an effective asexual
blood-stage vaccine are considerable. First, there is the difﬁ-
culty in deciding what type of immune response needs to be
induced. Should this be directed at just inducing antibodies
that inhibit invasion or parasite growth with or without the
cooperation of phagocytic cells, or is it also important to
induce an antibody-independent proliferative T-cell response?
Second, nearly all of the blood-stage molecules investigated
so far show genetic diversity (polymorphism), so that the
immune response induced by a vaccine may be only strain-
speciﬁc [28]. Finally, there is considerable redundancy, giving
the parasite alternatives when, for example, one route of
invasion is blocked by vaccination.
There is now strong evidence that P. falciparum erythro-
cyte membrane protein I, expressed on the surface of P. fal-
ciparum-infected erythrocytes, plays major roles in both the
natural acquisition of immunity and the sequestration of this
parasite in small blood vessels, causing tissue damage. This
molecule is therefore an attractive vaccine candidate. How-
ever, the ability of this antigen to undergo sequential anti-
genic variation complicates its use as a vaccine [29]. There
are, however, two situations in which this is worth further
investigation. There is evidence that selected P. falciparum
erythrocyte membrane protein I variants are associated
with severe malaria, and vaccination against this subgroup
could conceivably be beneﬁcial. In addition, there is evi-
dence that a very select group of variants, notably one
termed VAR2CSA, is responsible for sequestration of P. fal-
ciparum in the placenta, raising the intriguing option of
developing a vaccine speciﬁcally designed to protect preg-
nant women [29,30].
As in the case of pre-erythrocytic vaccines, a whole para-
site approach has also been used to induce immunity against
blood-stage parasites. Naive volunteers who were infected
three times with about 30 P. falciparum-infected erythrocytes
and treated before the infection was patent were protected
against subsequent challenge. Protection was not associated
with antibody production, but volunteers mounted a strong
proliferative T-cell response [31].
Vaccines that impact on transmission
With the prospect of malaria elimination in an increasing
number of countries, vaccines that interrupt transmission,
recently termed vaccines that inhibit malaria transmission
[32], are attracting increasing attention.
Two approaches can be taken to the development of vac-
cines that block transmission. Any highly effective pre-eryth-
rocyte-stage vaccine will reduce transmission, as it will
greatly reduce the chance that the parasite will invade ery-
throcytes and hence be able to produce gametocytes and
transmit the infection. Blood-stage vaccines are less likely to
be able to achieve this unless they are almost totally effec-
tive, as even a low level of blood-stage infection may allow
production of a sufﬁcient number of gametocytes to sustain
transmission. The second approach is to target the sexual
stages of the parasite in the human host and early develop-
mental stages found in the mosquito. Vaccines based on the
gamete surface antigens, P230, P48/45 and HAP2, prevent
fertilization in the mosquito midgut, whereas those based on
the ookinete antigens, P25 and P28, induce antibodies that
prevent ookinetes from migrating across the midgut wall
(Table 5).
A positive aspect of this type of transmission-blocking vac-
cine is that it attacks the parasite at a vulnerable stage of its
TABLE 4. Asexual blood-stage vaccine strategies
Recombinant merozoite proteins involved in invasion of erythrocytes. Most
are derived from
Merozoite surface protein (MSP)-1
Apical merozoite antigen 1 (AMA1)
also
Erythrocyte-binding antigen 175
MSP3
Blood-stage combinations, e.g. MSP1 + MSP2 + ring-infected erythrocyte surface
antigen
Long synthetic peptides
MSP3 + glutamate rich protein
Viral vector prime-boost strategies, e.g.
Chimpanzee adenovirus AdCh63/AMA1+
Modiﬁed vaccinia antigen/AMA1
Combinations from different life-cycle stages, e.g.
Viral vector expression of thrombospondin-related adhesion
protein + AMA1 + MSP-1
CSP + AMA1 mimetopes
TABLE 5. Sexual-stage vaccine strategies
Antigens expressed in gametocytes and gametes, and involved in fertilization,
notably P48/45, P230 and HAP2, are used to induce immune responses that
prevent fertilization in the mosquito midgut. Antibodies against these proteins
are induced during infections, and this might serve to boost a response to
vaccination
Antibodies against P25 and P28 expressed only on zygote/ookinete stages in
the mosquito prevent invasion and penetration of the midgut wall and any
further development of the parasite
A similar effect can be produced experimentally by immune responses induced
against components of the mosquito gut wall
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life cycle, when it has to transfer from one host to another
and when its numbers are very small [13]. Early clinical trials
have been conducted with vaccines based on the ookinete
antigens of P. falciparum and P. vivax [33,34] with induction of
transmission-blocking antibodies, but no large-scale clinical
trial of a transmission-blocking vaccine has yet been under-
taken. Another interesting experimental approach to trans-
mission blocking is to focus on the vector rather than the
parasite, by vaccinating with components of mosquito gut or
salivary glands that kill the feeding mosquito or reduce its
fecundity or lifespan, and hence its ability to transmit [13,35].
Alternative vaccine strategies
Most of the studies of vaccines described above have relied
on conventional vaccine technologies—the use of whole
organisms or proteins expressed in bacteria or yeasts. How-
ever, several other strategies have been explored. Studies
with DNA vaccines gave promising results in rodent malarias
but, in humans, DNA vaccines have proved to be less immu-
nogenic [36], and this approach is now receiving less atten-
tion. A more promising approach has been expression of
parasite antigens in viral vectors given in heterologous
prime-boost regimens, with a viral-vectored vaccine followed
either by a protein vaccine or by a different viral vector.
High-level T-cell responses and protection in some volun-
teers have been achieved with vaccines based on the sporo-
zoite antigen thrombospondin-related adhesion protein given
with two different viral vectors—fowlpox and modiﬁed vac-
cinia virus [37]. More recently, even higher T-cell responses
have been produced with thrombospondin-related adhesion
protein expressed in a chimpanzee adenovirus vector [38].
Adenovirus-based vaccines have also been shown to
induce strong antibody responses to the blood-stage and
sexual-stage parasites [39–41]. Microarray technologies [42]
provide opportunities to investigate many new antigens as
potential vaccine candidates [43,44].
Evaluation of Malaria Vaccines
The use of new techniques has accelerated the rate at which
new vaccine candidates can be developed in the laboratory.
A major challenge now is selecting those that warrant fur-
ther clinical evaluation.
Animal studies
The initial stage in the evaluation of a new vaccine candidate
is usually the demonstration of immunogenicity, either
humoral or cellular, in a small-animal model. The value of
these initial studies is enhanced if the immune response is
associated with protection. In the case of malaria, the best
developed functional assay is one that measures the ability of
antibodies to block infection of mosquitoes fed on blood
containing gametocytes [45]. Measurement of antibodies that
inhibit the growth of cultured blood-stage parasites in vitro,
either alone or in combination with white blood cells, has
also proved to be a useful screening assay for blood-stage
candidate vaccines [46]. It has proved more difﬁcult to
develop reproducible bioassays for pre-erythrocytic vaccines.
P. vivax presents a particular problem, as it is difﬁcult to cul-
ture this parasite in vitro, and no functional assay has yet
been developed for P. vivax hypnozoites. Humanized mice
that can be infected with parasitized human erythrocytes
[47] or that can support human liver stages [21] provide a
model that falls between in vitro assays and animal challenge
studies.
Whether non-human primate challenge studies constitute
an essential step in malaria vaccine development is debated
[48], as all non-human primate models have weaknesses, and
there is now a trend towards moving more rapidly into
human studies than has been the case in the past.
Evaluation in humans
Evaluation of malaria vaccines in humans follows the tradi-
tional pathway from phase 1 safety and immunogenicity stud-
ies in a small number of subjects through medium-sized
phase 2 efﬁcacy studies to large-scale phase 3 registration
trials.
An unusual feature of malaria vaccine development has
been the increasing use of phase 2a challenge studies in non-
immune volunteers. Experimental infections can be induced
with either bites by experimentally infected mosquitoes [49]
or inoculation of a small volume of infected blood obtained
from a very carefully screened donor [50], the latter giving
more consistent infections. The challenge model, now used
in over 1000 volunteers, has proved to be remarkably safe,
and when PCR is used to detect early infections [51], many
volunteers receive treatment before developing signiﬁcant
symptoms. Challenge studies with the RTS,S vaccine have
been good predictors of the outcome in ﬁeld trials [17], but
with some other vaccines this has not been the case [52].
Because of safety concerns, early malaria vaccine candi-
dates were taken through a series of age de-escalation tri-
als, but there is now an increasing willingness to move
more rapidly into trials in young children, the primary tar-
get in endemic areas, once immunogenicity and safety have
been demonstrated in adults from an endemic area. Evalua-
tion of the efﬁcacy of malaria vaccines in reducing transmis-
sion will be challenging. Such studies will need to be
community rather than individually randomized trials, and
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such trials will be large and expensive. If the membrane
feeding assay can be standardized [53] and shown to be a
reliable predictor of success in the ﬁeld, this will greatly
facilitate the development of vaccines directed at sexual
stages of the parasite.
How will Malaria Vaccines be Used?
It is likely that the ﬁrst malaria vaccine to be licensed will be
RTS,S/ASO1. Initial trials suggest that RTS,S will give about
50% protection against both uncomplicated and severe epi-
sodes of malaria that persists for at least 2 years, and the
vaccine therefore has the potential to prevent many deaths
[17]. It is not likely that RTS,S, deployed in a limited segment
of the population of high-transmission areas, will have any
signiﬁcant impact on malaria transmission. How, therefore,
might this vaccine best be deployed? A sensible strategy for
the introduction of RTS,S will be to give priority to the areas
where malaria is not yet controlled because existing control
measures cannot be deployed effectively or are ineffective. In
these areas, a vaccine that provided 50% protection for a
period of 2 years would be a sound investment. However, in
areas where malaria transmission persists but is well con-
trolled with existing measures and causes little morbidity or
mortality, introduction of a vaccine such as RTS,S, directed
primarily at the prevention of clinical disease, would be less
cost-effective. Where the boundary between these two epi-
demiological situations lies is uncertain, and may be inﬂu-
enced by the costs of the vaccine.
It is currently proposed to give RTS,S at the ages of 2, 3
and 4 months, possibly with a booster dose during the sec-
ond year of life. This schedule was chosen partly because it
ﬁts in well with the current schedule of administration of
routine paediatric vaccines, and partly because the main bur-
den of severe malaria in highly endemic areas is in children
during their ﬁrst 2 years of life. However, as the level of
malaria transmission declines, the age of cases increases, so
that an increasing proportion of cases of malaria are seen in
older children. In such circumstances, focusing malaria vacci-
nation on just the ﬁrst year of life may no longer be the
most appropriate strategy, unless the vaccine gives prolonged
protection, and infant immunization may need to be supple-
mented by additional catch-up strategies, including mass vac-
cination campaigns for older children. Selected groups of
high-risk subjects, such as pregnant women, patients with
human immunodeﬁciency virus infection and those with hae-
moglobinopathies, may also warrant priority.
In areas where malaria is reasonably well controlled, the
primary objective of malaria vaccination will be to reduce
and, eventually, interrupt transmission. This will require vac-
cination of the whole population. The level of coverage
required to interrupt transmission will be determined by
local epidemiological circumstances, but modelling suggests
that, in many circumstances, 90% coverage of the whole pop-
ulation with a vaccine with an efﬁcacy of over 90% will be
required to completely interrupt transmission, a daunting
challenge.
Challenges for the Future
Future malaria vaccine development faces a number of major
challenges, the biggest one of which is probably ﬁnancial
(Table 6).
Technical challenges
The increasing ability to make large numbers of vaccine con-
structs quickly with viral vector or other technologies is
removing one of the constraints faced by early vaccine devel-
opers. This ability is especially important in the development
of vaccines based on parasite antigens that shows substantial
antigen polymorphism, as is the case for many erythrocyte
antigens being considered as potential vaccine antigens.
Another important technical challenge for the coming years
will be ﬁnding the optimum ways of identifying the most
promising antigens to take forward into clinical development.
This down-selection process will probably have to depend
primarily on in vitro biological assays, and it is important that
research continues on improving the biological relevance,
reproducibility and high-throughput features of such assays
for each of the stages of the parasite’s life cycle.
Once a decision has been made to take forward a promis-
ing candidate to clinical development, a major challenge for
academic investigators, the group most likely to have under-
taken this work, is production of the good manufacturing
practice material that allows ﬁrst-into-human studies to be
undertaken. A number of ideas have been suggested with
regard to how this process could be facilitated, such as the
creation of publicly supported good manufacturing practice
facilities that could be used by academic groups to facilitate
TABLE 6. Approaches to the acceleration of malaria vac-
cine development
Focusing on new antigens characterized by genomic analysis as being likely to have
vaccine potential, e.g. surface expression. Most efforts so far have focused on
antigens characterized by protein chemistry decades ago
Provision of multiple-use good manufacturing practice facilities that will allow the
production of test batches of vaccine for academic investigators quickly and
at affordable cost
Optimization of in vitro assays that will allow rapid, biologically meaningful
screening of vaccine candidates, e.g. transmission-blocking growth inhibition assays
More ﬂexible regulatory processes
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the development of vaccines against several neglected dis-
eases [54].
Regulatory issues
It is uncertain how the second generation of disease-con-
trol malaria vaccines will achieve licensure. Assuming that
RTS,S becomes licensed, will the regulators require manu-
facturers to show that the new vaccine is superior to or at
least non-inferior to RTS,S in an efﬁcacy trial? The sample
size required for such a trial would be very large. In the
case of other infections, such as those caused by pneumo-
cocci or meningococci, second-generation vaccines have
been licensed on the basis of an immunological assay.
Whether this will ever be possible for malaria vaccines is
uncertain.
It is unlikely that any of the early generation of malaria
vaccines based on a single antigen will have the level of efﬁ-
cacy needed to interrupt transmission in highly endemic
areas, and this will probably require combination vaccines.
These might be vaccines containing multiple antigens of a
similar type, a combination of two different formulations of
the same antigen inducing different kinds of immune
response, or a combination of antigens from different stages
of the parasite’s life cycle. Finding the best way of combining
individual vaccines that have each shown partial protection is
going to be extremely challenging.
Financial issues
The development of RTS,S has been a long and expensive
process, and has only been possible because of the generos-
ity of the Bill and Melinda Gates Foundation, GSK and other
donors. Whether other promising vaccine candidates will be
able to attract ﬁnancial support on this scale is uncertain.
Malaria vaccines are likely to be relatively expensive in rela-
tion to other vaccines, especially if multiple components
produced with different technologies are required. Thus,
even if these vaccines are sold at or near to the price of
manufacture, there are likely to be major ﬁnancial con-
straints on the rapid deployment of malaria vaccines in the
areas where they could contribute most to malaria control
or elimination. The international community is already strug-
gling to ﬁnd the ﬁnancial resources to support the introduc-
tion of highly effective meningococcal, pneumococcal and
rotavirus vaccines in poor countries, and addition of malaria
vaccines to this list will provide an additional major chal-
lenge, but ways must be found of doing this. The recent,
renewed commitment of the international donor community
to the Global Alliance for vaccines and Immunization is
encouraging it would be a major tragedy if, after 50 years of
scientiﬁc endeavour, the ﬁrst generation of successful
malaria vaccines failed to reach those in the poorest coun-
tries of the world, where effective protection against malaria
is needed most.
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